Acute Respiratory Distress Syndrome (ARDS) Respiratory
Conditions
Interventions
Participants will be randomised to intervention or comparator by computer programme.
The intervention will be Baricitinib (Olumiant) 4 mg orally, once daily for 3 days.
Comparator is no interventi
Sponsors
Belfast Health and Social Care Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Healthy non-smoking adults aged 18-45 years old
Exclusion criteria
Exclusion criteria: 1. Age 45 years 3. BMI >30 kg/m² 4. On concomitant medications including over-the-counter medications excluding hormonal contraception and paracetamol 5. Previous adverse reactions to LPS, lignocaine or sedative agents 6. Pregnant or breast-feeding 7. Participation in a clinical trial of an investigational medicinal product within 30 days 8. Consent declined 9. History of asthma or other respiratory conditions 10. Smoking or e-cigarette use 11. Marijuana use or other inhaled products (with or without nicotine) in the last 3 months 12. Alcohol abuse, as defined by the Alcohol Use Disorders Identification Test (AUDIT) 13. Subjects with history of prior conventional cigarette (> 100 cigarettes lifetime and smoking within 6 months) or electronic cigarette use. 14. Live vaccine with in preceeding 4 weeks 15. Abnormal blood count, renal function or liver function tests identified at screening 16. History of shingles 17. History of Hepatitis B/C 18. Allergy to Baricitinib
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Broncho-alveolar lavage neutrophil count during bronchoscopy at day 4 | — |
Secondary
| Measure | Time frame |
|---|---|
| Broncho-alveolar lavage fluid/Plasma/Urine: cytokines including but not limited to Il-6, IL-10, IL-18, CXCL8, IL-1b, markers of epithelial and endothelial injury including but not limited to RAGE, SP-D, Ang2, single-cell RNA sequencing, plasma differential white cell count, BAL differential white cell count, plasma C-reactive protein | — |
Countries
Northern Ireland, United Kingdom
Outcome results
None listed